Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Springworks Therapeutics Inc (SWTX)

Springworks Therapeutics Inc (SWTX)
35.20 x 4 38.00 x 2
Post-market by (Cboe BZX)
36.35 +1.72 (+4.97%) 01/21/25 [NASDAQ]
35.20 x 4 38.00 x 2
Post-market 36.35 unch (unch) 16:20 ET
Quote Overview for Tue, Jan 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
34.63
Day High
37.59
Open 34.86
Previous Close 34.63 34.63
Volume 1,303,415 1,303,415
Avg Vol 1,529,751 1,529,751
Stochastic %K 23.72% 23.72%
Weighted Alpha -15.73 -15.73
5-Day Change -0.66 (-1.78%) -0.66 (-1.78%)
52-Week Range 28.21 - 53.92 28.21 - 53.92
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,575,987
  • Shares Outstanding, K 74,386
  • Annual Sales, $ 5,450 K
  • Annual Income, $ -325,100 K
  • EBIT $ -300 M
  • EBITDA $ -299 M
  • 60-Month Beta 0.82
  • Price/Sales 18.37
  • Price/Cash Flow N/A
  • Price/Book 4.83

Options Overview Details

View History
  • Implied Volatility 129.83% ( +4.07%)
  • Historical Volatility 75.36%
  • IV Percentile 98%
  • IV Rank 68.02%
  • IV High 169.36% on 01/10/25
  • IV Low 45.76% on 09/03/24
  • Put/Call Vol Ratio 0.03
  • Today's Volume 1,778
  • Volume Avg (30-Day) 1,530
  • Put/Call OI Ratio 0.47
  • Today's Open Interest 10,814
  • Open Int (30-Day) 12,381

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.66
  • Number of Estimates 6
  • High Estimate -0.48
  • Low Estimate -0.78
  • Prior Year -1.44
  • Growth Rate Est. (year over year) +54.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.95 +13.75%
on 01/15/25
Period Open: 35.59
45.65 -20.37%
on 01/07/25
+0.76 (+2.14%)
since 12/20/24
3-Month
28.21 +28.86%
on 10/24/24
Period Open: 30.49
45.65 -20.37%
on 01/07/25
+5.86 (+19.22%)
since 10/21/24
52-Week
28.21 +28.86%
on 10/24/24
Period Open: 39.84
53.92 -32.59%
on 03/08/24
-3.49 (-8.76%)
since 01/19/24

Most Recent Stories

More News
SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down

SpringWorks Therapeutics SWTX announced preliminary net product revenues for fourth-quarter and full-year 2024 for its sole marketed drug, Ogsiveo (nirogacestat). The drug is approved for treating adult...

CTMX : 0.8700 (+3.57%)
VYGR : 5.22 (+2.96%)
CSTL : 26.72 (+7.14%)
SWTX : 36.35 (+4.97%)
SpringWorks Therapeutics Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates at 43rd Annual J.P. Morgan Healthcare Conference

SWTX : 36.35 (+4.97%)
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SWTX : 36.35 (+4.97%)
SpringWorks Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

SWTX : 36.35 (+4.97%)
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As many biotech companies within the oncology space begin to roll...

ONCY : 0.8360 (+5.69%)
IOVA : 5.88 (-0.51%)
SNDX : 13.67 (+4.51%)
ONC.TO : 1.18 (unch)
IBRX : 3.22 (+9.52%)
SWTX : 36.35 (+4.97%)
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon

/CNW/ -- USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their end-of-quarter results, the American...

ONCY : 0.8360 (+5.69%)
IOVA : 5.88 (-0.51%)
SNDX : 13.67 (+4.51%)
ONC.TO : 1.18 (unch)
IBRX : 3.22 (+9.52%)
SWTX : 36.35 (+4.97%)
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark

SpringWorks Therapeutics, Inc. SWTX incurred a loss of 72 cents per share in the third quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had reported...

IMCR : 30.00 (+3.38%)
CSTL : 26.72 (+7.14%)
ANIP : 58.35 (-0.19%)
SWTX : 36.35 (+4.97%)
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference

SWTX : 36.35 (+4.97%)
SpringWorks Therapeutics: Q3 Earnings Snapshot

SpringWorks Therapeutics: Q3 Earnings Snapshot

SWTX : 36.35 (+4.97%)
SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

SWTX : 36.35 (+4.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics...

See More

Key Turning Points

3rd Resistance Point 40.72
2nd Resistance Point 39.15
1st Resistance Point 37.75
Last Price 36.35
1st Support Level 34.79
2nd Support Level 33.22
3rd Support Level 31.82

See More

52-Week High 53.92
Fibonacci 61.8% 44.10
Fibonacci 50% 41.06
Fibonacci 38.2% 38.03
Last Price 36.35
52-Week Low 28.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Master Swing Trading: Strategies for Momentum and Trends